Base to Base biotech podcast 18: NETs and AI to tackle antimicrobial resistance

This week, we have conversations with Eduardo Bravo, CEO of Citryll, and Dermot Tierney, COO of AMPLY Discovery.Interview times:02:53 Citryll21:56 AMPLY DiscoveryCitryllCitryll’s recent Series B financing of €85m at the end of last year is helping to advance its first-in-class therapy targeting neutrophil extracellular traps (NETs).Discovered in 2004, NETs are web-like structures released by white blood cells that are now understood to be fundamental drivers of inflammation - yet they've never been successfully targeted therapeutically.Three major strategic investors are backing this novel biological approach, suggesting potential for a new therapeutic class. Following phase 1 completion, Citryll is advancing into Phase 2a trials in both rheumatoid arthritis and hidradenitis suppurativa.We spoke with Bravo about the implications of targeting this newly understood biological pathway and the potential market impact.AMPLY DiscoveryAMPLY Discovery is an AI company finding nature's own solutions to drug-resistant infections.Dermot Tierney is COO of AMPLY Discovery, a Queen's University Belfast spinout that's taken a different approach to the AMR crisis. Instead of trying to design new antimicrobials from scratch, they're using AI to discover what evolution already perfected over millions of years.The AMPLY platform connects the digital biological biome to high volume peptide, protein and RNAi extraction technology to unlock a new frontier in drug discovery.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]